Zymeworks (ZYME) Free Cash Flow Growth (1y) (2022 - 2026)
Zymeworks (ZYME) Free Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | -1,238.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,238.53% |
| Dec 31, 2025 | 74.08% |
| Sep 30, 2025 | -369.42% |
| Jun 30, 2025 | 144.85% |
| Mar 31, 2025 | 90.91% |
| Dec 31, 2024 | -362.57% |
| Sep 30, 2024 | 84.45% |
| Jun 30, 2024 | -257.88% |
| Mar 31, 2024 | 54.92% |
| Dec 31, 2023 | -95.14% |
| Sep 30, 2023 | 35.53% |
| Jun 30, 2023 | 87.47% |
| Mar 31, 2023 | -40.30% |
| Dec 31, 2022 | 745.43% |